Teva 4Q13 4Q Revenues: $5.4 billion (+3%) 4Q Earnings: $380 million (+19%) FY Revenues: $20.3 billion (flat) FY Earnings: $1.3 billion (-34%) Comments: Generic revenues were up 1% in 4Q to $2.7 billion (including $163 million in third-party API sales), with U.S. revenues growing 14% to $1.2 billion, driven by exclusive launches of generics for Niaspan, Temodar, Cymbalta and Tobi. Sales of specialty medicines grew 5% in 4Q to $2.2 billion, driven by Copaxone and Treanda. Copaxone revenues we...